Stroke

375

Pipeline Programs↗

165

Active Trials↗

105

Companies Involved↗

Stroke is a highly competitive landscape with 375 programs across 105 companies. The most active players are Jeil Pharmaceutical Co., Ltd., EMD Serono, Biocells (Beijing) Biotech Co.,Ltd. 74 therapies are approved with 99 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

83/100

Mech. Concentration

5/100

Completion Rate

77/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Jeil Pharmaceutical Co., Ltd.

1 program

EMD Serono

1 program

Biocells (Beijing) Biotech Co.,Ltd

2 programs

Remedy Pharmaceuticals, Inc.

1 program

ARCA Biopharma, Inc.

1 program

Asahi Kasei Pharma Corporation

1 program

Pipeline

Programs by Phase

Preclinical66

Dabigatran

Boehringer Ingelheim

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Alteplase

Roche

Midodrine

Takeda

Losartan Potassium

Merck & Co.

Phase 121

Ketamine

Aultman Health Foundation

Interferon Beta-1a

EMD Serono

Tizanidine

Legacy Health System

Phenylephrine

Exela Pharma Sciences, LLC.

Lisinopril

Twinpig Biolab, Inc.

Phase 2115

Levosimendan

Orion Corporation, Orion Pharma

Semaglutide

Novo Nordisk

Epoetin Beta

Roche

Rotigotine

UCB

Ghrelin

University of Aarhus

Phase 399

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Tenecteplase

Roche

Tocilizumab

Roche

Eptifibatide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Approved74

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Valsartan

Novartis

Remifentanil

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Propofol

Fresenius Kabi Oncology Ltd.

Telmisartan

Boehringer Ingelheim

Analysis

Modality Breakdown

92%

Small molecule

395 of 430 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 430 classified programs, each share of the total. Modality classified for 99% of 462 pipeline programs.

Analysis

Trial Status

584

clinical trials

Completed248 · 42%

Recruiting101 · 17%

Unknown status94 · 16%

Terminated49 · 8%

Not yet recruiting45 · 8%

Withdrawn23 · 4%

Other24 · 4%

Clinical Trials

Trial Activity

584 trials

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT07043686·30 enrolled

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07092709·912 enrolled

Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke

Recruiting·XXinqiao Hospital of Chongqing·Phase 2/3·NCT05728333·800 enrolled

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Recruiting·KKafrelsheikh University·Phase 4·NCT06653946·716 enrolled

Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

Recruiting·—·N/A·NCT05683873·130 enrolled

Lyon Registry of Stroke Treated by Thrombolysis or Thrombectomy

Recruiting·HHospices Civils de Lyon·N/A·NCT04620642·4,500 enrolled

Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Recruiting·ZZhejiang Provincial People's Hospital·Phase 3·NCT06530537·848 enrolled

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591377·900 enrolled

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

Recruiting·—·N/A·NCT04948749·792 enrolled

MPR for Stroke Risk Assessment of ICAS

Recruiting·XXuanwu Hospital, Beijing·N/A·NCT07309718·400 enrolled

Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

Recruiting·XXinqiao Hospital of Chongqing·Phase 3·NCT06987305·820 enrolled

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting·YYale University·Phase 3·NCT03907046·700 enrolled

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

Recruiting·TThe Florey Institute of Neuroscience and Mental Health·Phase 2·NCT05363397·80 enrolled

SURGERY VS BOTULINUM TOXIN ON QUALITY OF LIFE IN STROKE PATIENTS: RANDOMIZED TRIAL

Recruiting·FFundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental·N/A·NCT06392633·44 enrolled

Endovascular Acute Stroke Intervention - Tandem OCclusion Trial

Recruiting·—·N/A·NCT04261478·458 enrolled

Page 1 of 39

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)